Why insider trading matters?

When insiders buy shares on the open market, this can thus be regarded as a strong endorsement by those that know the company the best -- they are literally betting their own money on the company's future. Insider selling, however, is not necessarily meaningful in any way, as there is a range of reasons for insiders to liquidate (some) of the shares they own.

- Seeking Alpha
Edesa Biotech, Inc. (EDSA)
Sector: Healthcare; Industry: Biotechnology

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the development and advancement of treatments for dermatological and gastrointestinal indications. Edesa Biotech, Inc. has a collaborative research project with the National Research Council of Canada to develop novel immunotherapies for vitiligo, as well as other indications; and Light Chain Bioscience for the development and commercialization of two Phase 2-ready biologic drug candidates for various therapeutic, prophylactic, and diagnostic applications. The company was founded in 2015 and is headquartered in Markham, Canada.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2020-03-29 Nijhawan Pardeep Chief Executive Officer Buy 2,000 $5.23 $10,460 No
2021-03-25 Nijhawan Pardeep Chief Executive Officer Buy 3,000 $5.25 $15,750 No
2021-03-24 Nijhawan Pardeep Chief Executive Officer Buy 5,000 $5.16 $25,800 No
2020-05-26 Nijhawan Pardeep Chief Executive Officer Buy 3,000 $2.98 $8,939 No
2020-03-17 Nijhawan Pardeep Chief Executive Officer Buy 5,000 $1.87 $9,373 No

Insider Smart

Axsome Therapeutics, Inc (AXSM) - AXSM shows the power of an #allgreen stock, no insider selling, great management great company, if you follow the insiders last year and pick up around $25, the 52 week high is $100+.

Insider Smart

Altimmune, Inc. (ALT) - Venrock Healthcare Capital Partners III, L.P., 10%-owner of ALT bought 1.3M shares in late May then added another 1.5M shares in June with an averaged ~$8 per share. 10 days after the accumulation, ALT price jumped to $10.